126 related articles for article (PubMed ID: 15493361)
21. What to do with IL-2?
Dillman RO
Cancer Biother Radiopharm; 1999 Dec; 14(6):423-34. PubMed ID: 10850329
[TBL] [Abstract][Full Text] [Related]
22. Myocarditis associated with immune checkpoint inhibitor therapy: a case report of three patients.
Ansari-Gilani K; Tirumani SH; Smith DA; Nelson A; Alahmadi A; Hoimes CJ; Ramaiya NH
Emerg Radiol; 2020 Aug; 27(4):455-460. PubMed ID: 32130542
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-2.
Med Lett Drugs Ther; 1990 Sep; 32(826):85-6. PubMed ID: 2202892
[No Abstract] [Full Text] [Related]
24. Interleukin 2 in cancer therapy.
Antony GK; Dudek AZ
Curr Med Chem; 2010; 17(29):3297-302. PubMed ID: 20712575
[TBL] [Abstract][Full Text] [Related]
25. Biopsy evidence of atrial myocarditis in an athlete developing transient sinoatrial disease.
Frustaci A; Cameli S; Zeppilli P
Chest; 1995 Nov; 108(5):1460-2. PubMed ID: 7587462
[TBL] [Abstract][Full Text] [Related]
26. Angioneurotic oedema and urticaria during therapy with interleukin-2 (IL-2).
Baars JW; Wagstaff J; Hack CE; Wolbink GJ; Eerenberg-Belmer AJ; Pinedo HM
Ann Oncol; 1992 Mar; 3(3):243-4. PubMed ID: 1586626
[No Abstract] [Full Text] [Related]
27. A review of recent findings involving interleukin-2-based cancer therapy.
Eklund JW; Kuzel TM
Curr Opin Oncol; 2004 Nov; 16(6):542-6. PubMed ID: 15627015
[TBL] [Abstract][Full Text] [Related]
28. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma.
Guleria AS; Yang JC; Topalian SL; Weber JS; Parkinson DR; MacFarlane MP; White RL; Steinberg SM; White DE; Einhorn JH
J Clin Oncol; 1994 Dec; 12(12):2714-22. PubMed ID: 7989949
[TBL] [Abstract][Full Text] [Related]
29. Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma.
Clark JM; Kelley B; Titze J; Fung H; Maciejewski J; Nathan S; Rich E; Basu S; Kaufman HL
Oncology; 2013; 84(2):123-6. PubMed ID: 23235386
[TBL] [Abstract][Full Text] [Related]
30. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.
McDermott DF; Trehu EG; Mier JW; Sorce D; Rand W; Ronayne L; Kappler K; Clancy M; Klempner M; Atkins MB
Clin Cancer Res; 1998 May; 4(5):1203-13. PubMed ID: 9607578
[TBL] [Abstract][Full Text] [Related]
31. Symptomatic exacerbation of Crohn disease after treatment with high-dose interleukin-2.
Sparano JA; Brandt LJ; Dutcher JP; DuBois JS; Atkins MB
Ann Intern Med; 1993 Apr; 118(8):617-8. PubMed ID: 8452327
[No Abstract] [Full Text] [Related]
32. Progressive anemia following combination therapy with interferon-alpha and interleukin-2 in a patient with metastatic renal cell carcinoma.
Hosokawa Y; Kishino T; Ono T; Oyama N; Hayashi K; Momose H
Int J Urol; 2004 Oct; 11(10):906-8. PubMed ID: 15479299
[TBL] [Abstract][Full Text] [Related]
33. Acute myocardial infarction and left ventricular aneurysm in a patient with normal coronary arteries.
Li YH; Lai LP; Liau CS; Tsai CC
Cardiology; 1993; 83(4):280-4. PubMed ID: 8281545
[TBL] [Abstract][Full Text] [Related]
34. High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard.
Dutcher JP
Oncology (Williston Park); 2011 Apr; 25(5):427-8. PubMed ID: 21710841
[No Abstract] [Full Text] [Related]
35. High-dose interleukin 2-induced myocarditis: can myocardial damage reversibility be assessed by cardiac MRI?
Chow S; Cove-Smith L; Schmitt M; Hawkins R
J Immunother; 2014 Jun; 37(5):304-8. PubMed ID: 24810642
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
37. Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon alpha in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment.
Huland E; Heinzer H; Huland H
J Cancer Res Clin Oncol; 1994; 120(4):221-8. PubMed ID: 8288676
[TBL] [Abstract][Full Text] [Related]
38. Plasma nitrate plus nitrite changes during continuous intravenous infusion interleukin 2.
Citterio G; Pellegatta F; Lucca GD; Fragasso G; Scaglietti U; Pini D; Fortis C; Tresoldi M; Rugarli C
Br J Cancer; 1996 Oct; 74(8):1297-301. PubMed ID: 8883421
[TBL] [Abstract][Full Text] [Related]
39. Aldesleukin for metastatic renal cell carcinoma?
Drug Ther Bull; 1993 Apr; 31(8):29-30. PubMed ID: 8348884
[No Abstract] [Full Text] [Related]
40. High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer.
Shablak A; Sikand K; Shanks JH; Thistlethwaite F; Spencer-Shaw A; Hawkins RE
J Immunother; 2011 Jan; 34(1):107-12. PubMed ID: 21150719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
